FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096656254> ?p ?o ?g. }

• W2096656254 endingPage "1109" @default.
• W2096656254 startingPage "1109" @default.
• W2096656254 abstract "Journal of Mass SpectrometryVolume 40, Issue 8 p. 1109-1109 JMS Letter Avilamycin did not play a role in the discontinuation of evernimicin as a clinical drug candidate Aimee E. Belanger, Corresponding Author Aimee E. Belanger Elanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USAElanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USA.===Search for more papers by this authorThomas R. Shryock, Thomas R. Shryock Elanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USASearch for more papers by this author Aimee E. Belanger, Corresponding Author Aimee E. Belanger Elanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USAElanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USA.===Search for more papers by this authorThomas R. Shryock, Thomas R. Shryock Elanco Animal Health, 2001 West Main Street, Greenfield, Indiana, 46140, USASearch for more papers by this author First published: 22 July 2005 https://doi.org/10.1002/jms.889Citations: 4Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Eichhorn P, Pérez S, Bechtholt A, Aga DS. Fragmentation studies on the antibiotic avilamycin A using ion trap mass spectrometry. J. Mass Spectrom. 2004; 39: 1541. 2Shryock TR. Will avilamycin convert ziracine in zerocine? Emerg. Infect. Dis. 2001; 7: 488. 3 Schering-Plough Discontinues ZIRACIN(TM) Clinical Development, http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/05-05-2000/0001210676. [accessed 2005]. 4 Ziracin MT Desk Glossary and Terms, http://www.mtdesk.com/frame.php?frame=glossary. [accessed 2005]. 5Aarestrup FM. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Microb. Drug Resist. 1998; 4: 137. 6Schouten MA, Voss A, Hoogkamp-Korstanje JAA. The European VRE Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob. Agents Chemother. 1999; 43: 2542. 7Kropec A, Frank U, Jonas D, Thriene W, Schmidt-Eisenlohr E, Dieter Daschner F. In vitro susceptibility to everninomycin of Gram-positive nosocomial pathogens isolated from intensive care units in Germany. Chemotherapy 2001; 47: 15. 8Jones RN, Hare RS, Sabatelli FJ. Ziracin Susceptibility Testing Group. In vitro Gram-positive antimicrobial activity of evernimicin (SCH27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial. J. Antimicrob. Chemother. 2001; 47: 15. 9Aarestrup FM, McNicholas PM. Incidence of high-level evernimicin resistance in Enterococcus faecium among food animals and humans. Antimicrob. Agents Chemother. 2002; 46: 3088. 10Rennie RP, Jones RN, Mutnick AH. SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn. Microbiol. Infect. Dis. 2003; 45: 287. 11Courvalin P. Will avilamycin convert ziracine into zerocine? Emerg. Infect. Dis. 2000; 6: 558. 12Courvalin P. The antibiotic food-chain gang. Emerg. Infect. Dis. 2001; 7: 489. Citing Literature Volume40, Issue8August 2005Pages 1109-1109 ReferencesRelatedInformation" @default.
• W2096656254 created "2016-06-24" @default.
• W2096656254 creator A5011797376 @default.
• W2096656254 creator A5064429548 @default.
• W2096656254 date "2005-07-22" @default.
• W2096656254 modified "2023-10-09" @default.
• W2096656254 title "Avilamycin did not play a role in the discontinuation of evernimicin as a clinical drug candidate" @default.
• W2096656254 cites W1993379336 @default.
• W2096656254 cites W2004893482 @default.
• W2096656254 cites W2011682266 @default.
• W2096656254 cites W2027338163 @default.
• W2096656254 cites W2077491736 @default.
• W2096656254 cites W2133816029 @default.
• W2096656254 cites W2135783500 @default.
• W2096656254 cites W2153777171 @default.
• W2096656254 cites W4250505314 @default.
• W2096656254 cites W4252276641 @default.
• W2096656254 doi "https://doi.org/10.1002/jms.889" @default.
• W2096656254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16041736" @default.
• W2096656254 hasPublicationYear "2005" @default.
• W2096656254 type Work @default.
• W2096656254 sameAs 2096656254 @default.
• W2096656254 citedByCount "4" @default.
• W2096656254 countsByYear W20966562542015 @default.
• W2096656254 countsByYear W20966562542016 @default.
• W2096656254 crossrefType "journal-article" @default.
• W2096656254 hasAuthorship W2096656254A5011797376 @default.
• W2096656254 hasAuthorship W2096656254A5064429548 @default.
• W2096656254 hasConcept C118552586 @default.
• W2096656254 hasConcept C15744967 @default.
• W2096656254 hasConcept C161191863 @default.
• W2096656254 hasConcept C205649164 @default.
• W2096656254 hasConcept C2778715236 @default.
• W2096656254 hasConcept C41008148 @default.
• W2096656254 hasConceptScore W2096656254C118552586 @default.
• W2096656254 hasConceptScore W2096656254C15744967 @default.
• W2096656254 hasConceptScore W2096656254C161191863 @default.
• W2096656254 hasConceptScore W2096656254C205649164 @default.
• W2096656254 hasConceptScore W2096656254C2778715236 @default.
• W2096656254 hasConceptScore W2096656254C41008148 @default.
• W2096656254 hasIssue "8" @default.
• W2096656254 hasLocation W20966562541 @default.
• W2096656254 hasLocation W20966562542 @default.
• W2096656254 hasOpenAccess W2096656254 @default.
• W2096656254 hasPrimaryLocation W20966562541 @default.
• W2096656254 hasRelatedWork W2014238892 @default.
• W2096656254 hasRelatedWork W2060361110 @default.
• W2096656254 hasRelatedWork W2360693916 @default.
• W2096656254 hasRelatedWork W2415484199 @default.
• W2096656254 hasRelatedWork W2419505618 @default.
• W2096656254 hasRelatedWork W2748952813 @default.
• W2096656254 hasRelatedWork W2899084033 @default.
• W2096656254 hasRelatedWork W3121096891 @default.
• W2096656254 hasRelatedWork W4320086256 @default.
• W2096656254 hasRelatedWork W2464739384 @default.
• W2096656254 hasVolume "40" @default.
• W2096656254 isParatext "false" @default.
• W2096656254 isRetracted "false" @default.
• W2096656254 magId "2096656254" @default.
• W2096656254 workType "article" @default.